L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats

Psychopharmacology

Volumn 143, Issue 3, 1999, Pages 235-243

  Konieczny, Jolanta ^a   Ossowska, Krystyna ^a   Schulze, Gert ^b   Coper, Helmut ^b   Wolfarth, Stanislaw ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Catalepsy; Glycine site; L 701,324; Muscle rigidity; NMDA receptor; Parkinson's disease; Rotarod

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 5,7 DICHLOROKYNURENIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; 7 CHLOROKYNURENIC ACID; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SPECIFICITY; ELECTROMYOGRAM; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MUSCLE RIGIDITY; MUSCLE TONE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-DYSKINESIA AGENTS; CATALEPSY; DOPAMINE ANTAGONISTS; ELECTROMYOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALOPERIDOL; MALE; MUSCLE RIGIDITY; MUSCLE TONUS; PARKINSON DISEASE, SECONDARY; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032913134     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050942     Document Type: Article

References (47)

1. Barbeau A (1969) L-Dopa therapy in Parkinson's disease. Can Med Assoc J 101:791-800
2. Birkmayer W, Hornykiewicz O (1961) Der 3,4-dioxyphenylalanin (=L-dopa)-Effect bei der Parkinson Akinese. Wien Klin Wochenschr 73:777-788
3. Bristow LJ, Landon L, Saywell KL, Tricklebank MD (1995) The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology 118:230-232
4. Bristow LJ, Flatman KL, Hutson PH, Kulagowski JJ, Leeson PD, Young L, Tricklebank MD (1996a) The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324 in rodents. J Pharmacol Exp Ther 277: 578-585
5. Bristow LJ, Hutson PH, Kulagowski JJ, Leeson PD, Matheson S, Murray F, Rathbone D, Saywell KL, Thorn L, Watt AP, Tricklebank MD (1996b) Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther 279:492-501
6. Carroll CB, Holloway V, Brothie JM, Mitchell IJ (1995) Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology 119:55-65
7. Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology 102:295-300
8. Crossman AR, Peggs D, Boyce S, Luquin Mr, Sambrook MA (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 28: 1271-1273
9. Ebert U, Wlaz P, Löscher W (1997) Anticonvulsant effects by combined treatment with a glycineB receptor antagonist and a polyamine site antagonist in amygdala-kindled rats. Eur J Pharmacol 322:179-184
10. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1236-1239
11. Kemp JA, Leeson PD (1993) The glycine site of the NMDA receptor: five years on. Trends Pharmacol Sci 14:20-25
12. Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12:285-286
13. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28:539-546
14. Kolasiewicz W, Baran J, Wolfarth S (1987) Mechanographic analysis of muscle rigidity after morphine and haloperidol: a new methodological approach. Naunyn-Schmiedeberg's Arch Pharmacol 335:449-453
15. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166:589-590
16. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human post-mortem brain study. Eur J Pharmacol [Mol Pharmacol Sect] 206:297-300
17. Kotliñska J, Liljequist S (1996) Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Psychopharmacology 123:238-244
18. Kretschmer BD, Schmidt WJ (1996) Behavioural effects mediated by the modulatory glycine site of the NMDA receptor in the anterodorsal striatum and nucleus accumbens. J Neurosci 16:1561-1569
19. 1 receptor mediated catalepsy in rats. J Neural Transm [Gen Sect] 95:123-136
20. Kretschmer BD, Kratzer U, Breithecker K, Koch M (1997) ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. Eur J Pharmacol 331:109-116
21. Laurie DJ, Seeburg PH (1994) Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol [Mol Pharmacol Sect] 268:335-345
22. Lee RG (1989) Pathophysiology of rigidity and akinesia in Parkinson's disease. Eur Neurol 29:13-18
23. Löschmann P-A, Lange KW, Kunow M, Rettig K-J, Jähnig P, Honor T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J Neural Transm [P-D Sect] 3:203-213
24. Lorenc-Koci E, Ossowska K, Wardas J, Wolfarth S (1995) Does reserpine induce parkinsonian rigidity? J Neural Transm [P-D Sect] 9:211-223
25. Lorenc-Koci E, Wolfarth S, Ossowska K (1996) Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109:268-276
26. Lorenc-Koci E, Konieczny J, Wolfarth S (1998) Contribution of the glycine site of the NMDA receptor in the rostral and intermediate-caudal parts of the striatum in the regulation of the muscle tone in rats. Brain Res 793:315-320
27. Maj J, Rogóz Z, Skuza G, Kolodziejczyk K (1994) Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7-dichlorokynurenic acid, glycine site antagonists. Pol J Pharmacol 46:115-124
28. 3H]D-AP5, suggesting down-regulation of the cortical N-methyl-D-aspartate receptors. Neuroscience 30:87-94
29. Mitchell IJ, Hughes N, Carroll CB, Brotchie JM (1995) Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav Pharmacol 6:492-507
30. Ossowska K (1994) The role of excitatory amino acids in experimental models. J Neural Transm [P-D Sect] 8:39-71
31. Ossowska K, Konieczny J (1996) NMDA receptors in the rostral and intermediate-caudal striatum play an opposite role in regulation of the muscle tone in rats. Pol J Pharmacol 48:261-267
32. Ossowska K, Smialowska M, Wolfarth S (1983) A biphasic influence of globus pallidus lesions: spontaneous catalepsy followed by anticataleptic effect. Pharmacol Biochem Behav 19:169-176
33. Ossowska K, Lorenc-Koci E, Wolfarth S (1994) Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. J Neural Transm [P-D Sect] 7: 143-152
34. Ossowska K, Lorenc-Koci E, Schulze G, Konieczny J, Wolfarth S, Bojarski M, Coper H (1996a) The role of reflex activity in the regulation of muscle tone in rats. Exp Physiol 81:211-223
35. Ossowska K, Lorenc-Koci E, Schulze G, Wolfarth S (1996b) The influence of dizocilpine (MK-801) on the reserpine-enhanced electromyographic stretch reflex in rats. Neurosci Lett 203: 73-76
36. Ossowska K, Lorenc-Koci E, Konieczny J, Wolfarth S (1998) The role of striatal glutamate receptors in models of Parkinson's disease. Amino Acids 14:11-15
37. Priestley T, Laughton P, Macaulay AJ, Hill RG, Kemp JA (1996) Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L701,324. Neuropharmacology 11:1573-1581
38. Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMDA receptor antagonist in the treatment of Parkinson's disease. J Neural Transm [P-D Sect] 4:277-282
39. Rowley M, Leeson PD, Stevenson GI, Moseley AM, Stansfield I, Sanderson I, Robinson L, Baker R, Kemp JA, Marshall GR, Foster AC, Grimwood S, Tricklebank MD, Saywell KL (1993) 3-Acetyl-4-hydroxyquinolin-2(H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex. J Med Chem 36: 3386-3396
40. Rupniak NMJ, Boyce S, Steventon MJ, Iversen SD, Marsden CD (1992) Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 32: 103-105
41. Schneider E, Fischer PA, Clemens R, Balzereit F, Funfgeld EW, Haase HJ (1984) Effects of oral memantine administration on Parkinson symptoms. Results of placebo-controlled multicenter study. Dtsch Med Wochenschr 109:987-990
42. Schwab RS, England AC, Poskanzer DC, Young RE (1969) Amantadine in the treatment of Parkinson's disease. JAMA 208:1168-1170
43. Steiger MJ, Quinn NP (1995) Levodopa-based therapy. In: Koller WC, Paulson G (eds) Therapy of Parkinson's disease (Neurological disease and therapy series, vol 34). Marcel Dekker, New York, pp 143-158
44. Stauch Slusher B, Rissolo KC, Jackson PF, Pullan LM (1994) Centrally-administered glycine antagonists increased locomotion in monoamine-depleted mouse. J Neural Transm [Gen Sect] 97:175-185
45. Wolfarth S, Kolasiewicz W, Ossowska K, Bober M (1992) Direct mechanomyographic measurement of the myorelaxant action of baclofen and diazepam in normal and reserpinized rats. Naunyn-Schmiedeberg's Arch Pharmacol 345:209-212
46. Wolfarth S, Konieczny J, Smialowska M, Schulze G, Ossowska K (1996) Influence of 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway on the muscle tone and electromyographic activity measured during passive movements. Neuroscience 74:985-996
47. Woodward RM, Huettner JE, Guastella J, Keana JFW, Weber E (1995) In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol 47:568-581